Hoosier Mama

Team...Galactic?

emerald — canonically went to school!

sapphire — someone get this girl a dyslexia diagnosis PLEASE i am BEGGING you

green (m) — has canonically read a book (giovanni’s ground type tips & tricks). likely has some foundational skills & became a sight reader over time, because his prime reading development years (generally ages 5-7ish) were spent learning martial arts & pokemon training. his sister became a doctor, so it’s likely she and green by extension have had some sort of schooling at some point.

silver — i think he also has canonically read a book (giovanni’s ground type tips & tricks) which is the only reason he is higher than blue (f) on this list.

crystal — works at a school. also, you almost definitely can’t get a job in a research lab without knowing how to read.

blue (f) — she and silver learned “everything they needed to know” from the mask of ice. I cannot see a world where that didn’t include learning to read, and they were kidnapped young enough that they’d be ready to start learning foundational reading skills. however, pryce doesn’t have a teaching certification and therefore it makes me question the quality of their education

gold — does not consider himself a reader and wouldn’t read a book for fun, but often admits to doing “research” on his own time, implying that he does, in fact, read. also, has an arguably normal childhood and likely received whatever the pokemon world considers a “formal education.” definitely needs an adhd diagnosis but that is a separate conversation

ruby — likely knows how to read. is definitely the kid who never wears their glasses during reading group.

yellow — canonically can write, implying she knows how to decode. fluent reading? unclear

This movie got made because Robin Williams said yes to it (and it's important that Gene Hackman did as well). Williams in the 90s was a mega-star of a type that's not present in the current media environment (maybe Tom Cruise, but I personally think that's echo from his salad days). Even his flops made money on the back end in the video rental market, which also doesn't exist anymore (streaming is different). Hackman was on the other side of his A-list career but still Hollywood nobility if not full royalty.

Playing gay was considered career suicide in the 90s. There had been a number of actors who put lie to that belief stretching back decades, but this was Williams and Hackman (yes, being on screen next to a gay character was enough to get you blacklisted) saying "screw that" and doing it anyway.

Being gay and out was career suicide in the 90s.

Nathan Lane had a really nice gig going for himself. The Lion King put him into the Disney rep company with people like Williams, Bette Midler, and Whoopie Goldberg (check their IMBD list from the 90s--they were making bank at Disney).

Lane didn't come out until several years later (nice summary: https://deadline.com/2024/06/nathan-lane-robin-williams-advice-coming-out-birdcage-1235975010/).

I don't want to imply that this was a Sorkinized moment where everything changed because of one thing, but this was a very important movie that caused real movement in the needle on queer acceptance.

no. he doesn't use emojis. i'm not kidding when i say i have seen him use one once in two years. everyone was shocked.

For millions of people managing type 2 diabetes, mornings begin the same way — a needle, a dose, and a quiet mental note to do it all again tomorrow.

That routine just changed.

On March 26, 2026, the U.S. Food and Drug Administration approved Awiqli (insulin icodec-abae), developed by Novo Nordisk, as the first and only once-weekly basal insulin ever approved for adults with type 2 diabetes in the United States.

This is not a minor update to an existing drug.

It is the first entirely new class of basal insulin to reach U.S. patients in more than two decades.

Instead of injecting insulin every single day, people with type 2 diabetes using Awiqli will only need one shot per week, on the same day, every week.

That means reducing from 365 injections a year down to just 52.

For anyone who has ever felt the weight of that daily ritual — the anxiety of forgetting, the physical discomfort, the constant reminder that their body needs help — this approval represents something much bigger than a dosing schedule.

It represents relief.

How the Drug Actually Works

Understanding why this injection lasts a full week requires a quick look inside the body.

Most traditional basal insulins are absorbed into the bloodstream and begin breaking down within 24 hours, which is why patients need a fresh dose every day to maintain stable blood sugar levels.

Awiqli works differently.

Its active ingredient, insulin icodec-abae, is engineered to loosely attach to a blood protein called albumin, which is found naturally and abundantly in the bloodstream.

This attachment creates a slow-release reservoir.

Instead of flooding the system and fading fast, the insulin releases gradually and consistently over an entire seven-day period, keeping blood sugar in a healthy range around the clock...

The FDA reviewed and ultimately declined to approve it for people with type 1 diabetes, citing concerns about a modestly increased risk of hypoglycemia in that population specifically.

Some regulatory agencies in other countries, including the European Union, Canada, Australia, and Japan, have approved Awiqli for both type 1 and type 2 diabetes, but for now the U.S. approval is limited to type 2...

What Comes Next

Awiqli is not standing alone in this space for long.

Eli Lilly is developing its own once-weekly basal insulin, called efsitora alfa, which is currently in late-stage clinical trials.

If that drug also earns FDA approval, it would give patients and doctors two once-weekly options to choose from, allowing for personalized decisions based on a patient’s health profile, insurance coverage, and individual response.

The broader direction of travel in diabetes care is unmistakable.

Fewer injections, smarter formulations, and better integration with digital tools like continuous glucose monitors and insulin-tracking apps are all converging toward a future where managing diabetes requires less daily mental effort without becoming any less medically precise...

A Small Shot With Large Implications

It is easy to look at a once-weekly injection and see only a scheduling change.

But the science behind Awiqli, the scale of the ONWARDS trials, and the consistent satisfaction reported by patients all point toward something that matters far more than convenience.

Diabetes management has always asked a lot of people.

It asks for daily vigilance, daily discipline, and a daily willingness to confront one’s own condition, sometimes in uncomfortable or inconvenient circumstances.

Anything that reduces that load, without reducing the quality of care, is worth taking seriously.

For the more than 37 million Americans living with diabetes, and the hundreds of millions more around the world, a simpler weekly routine could mean the difference between a treatment plan that works on paper and one that actually works in a person’s life.

That is the real significance of what the FDA approved on March 26, 2026.

Not just a new drug.

A new way of keeping people healthy, one week at a time.

I have a folder of these on my phone... I'm not sure what that says about me!